Outcome after Discontinuation of Second Generation Tyrosine Kinase Inhibitors (TKIs) Used As Frontline Therapy for Patients (pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML)

被引：0
|
作者：
Abdelall, Waleed
Kantarjian, Hagop M.
Devendra, K. C.
Akosile, Mary
Borthakur, Gautam
Verstovsek, Srdan
Daver, Naval
Pemmaraju, Naveen
Naqvi, Kiran
Garcia-Manero, Guillermo
Thompson, Philip A.
Ferrajoli, Alessandra
Ravandi, Farhad
Konopleva, Marina
DiNardo, Courtney D.
Jabbour, Elias J.
Cortes, Jorge E.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5248
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Outcome After Failure to Second Generation Thyrosine Kinase Inhibitors(TKI) Treatment as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase(CP)
    Eghtedar, Alireza
    Kantarjian, Hagop
    Jabbour, Elias
    o'Brien, Susan
    Quintas-Cardama, Alfonso
    Burton, Elizabeth
    Garcia-Manero, Guillermo
    Verstovsek, Srdan
    Konopleva, Marina
    Cortes, Jorge E.
    BLOOD, 2010, 116 (21) : 1411 - 1412
  • [2] Prognostic significance of prior best response to imatinib in patients (pts) with chronic myeloid leukemia (CML) in chronic phase (CP)Treated with second generation tyrosine kinase inhibitors (TKIs)
    Jabbour, Elias
    Kantarjian, Hagop
    Shan, Jenny
    O'Brien, Susan
    Wierda, William
    Ravandi, Farhad
    Borthakur, Gautant
    Komblau, Steven
    Walker, Brenda K.
    Rios, Mary Beth
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 577A - 577A
  • [3] Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy
    Boddu, Prajwal
    Jain, Preetesh
    Borthakur, Gautam
    Verstovsek, Srdan
    Garcia-Manero, Guillermo
    Daver, Naval
    Kadia, Tapan
    Ravandi, Farhad
    Jabbour, Elias
    Cortes, Jorge
    Kantarjian, Hagop
    LEUKEMIA & LYMPHOMA, 2019, 60 (13) : 3172 - 3180
  • [4] Kinetics of Molecular Response with Different Tyrosine Kinase Inhibitors (TKI) Used As Frontline Therapy in Chronic Myeloid Leukemia-Chronic Phase (CML CP)
    Naqvi, Kiran
    Kantarjian, Hagop M.
    Luthra, Rajyalakshmi
    Jabbour, Elias
    O'Brien, Susan
    Burton, Elizabeth M.
    Verstovsek, Srdan
    Ravandi, Farhad
    Wierda, William G.
    Borthakur, Gautam
    Quintas-Cardama, Alfonso
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 1616 - 1617
  • [5] Echocardiographic Findings in Patients (pts) Receiving Tyrosine Kinase Inhibitors (TKIs) for the Treatment of Chronic Myeloid Leukemia (CML)
    Gurguis, Christopher
    de Armas, Lizette Rodriguez
    Kantarjian, Hagop M.
    Boddu, Prajwal C.
    Jain, Preetesh
    Borthakur, Gautam
    Giza, Dana Elena
    Iliescu, Gloria
    Lopez-Mattei, Juan
    Kim, Peter
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Wierda, William G.
    Kornblau, Steven
    Jabbour, Elias J.
    Iliescu, Cezar
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [6] The Achievement of An Early Complete Cytogenetic Response (CCyR) Is A Major Determinant for Outcome In Patients (pts) with Early Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)
    Jabbour, Elias
    Kantarjian, Hagop M.
    Shan, Jenny
    O'Brien, Susan
    Kadia, Tapan
    Borthakur, Gautam
    Quintas-Cardama, Alfonso
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Cortes, Jorge
    BLOOD, 2010, 116 (21) : 1405 - 1405
  • [7] Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study
    Hughes, Timothy
    Rea, Delphine
    Boquimpani, Carla
    Minami, Yosuke
    Mauro, Michael
    Cortes, Jorge E.
    Apperley, Jane F.
    Gutierrez, Valentin Garcia
    Kapoor, Shruti
    Allepuz, Alex
    Quenet, Sarah
    Zhang, Yifan
    Hochhaus, Andreas
    BLOOD, 2022, 140 : 6757 - 6759
  • [8] Second generation tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia
    le Coutre, P.
    Baskaynak, G.
    Schwarz, M.
    Petereit, C.
    Westermann, J.
    Dorken, B.
    ANNALS OF ONCOLOGY, 2007, 18 : 17 - 17
  • [9] Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors
    Dahlen, Torsten
    Kockerols, Camille C. B.
    Ferreira, Germano
    Westerweel, Peter E.
    Mayer, Jiri
    Allepuz, Alex
    Wormser, David
    Yau, Lillian
    Zackova, Daniela
    BLOOD, 2022, 140 : 3889 - 3890
  • [10] Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) After Failure to 2nd and 3rd Tyrosine Kinase Inhibitors (TKIs).
    Li, Liunan
    Kantarjian, Hagop
    Zhao, Meng
    O'Brien, Susan
    Jabbour, Elias
    Quintas-Cardama, Alfonso
    Burton, Elizabeth
    Faderl, Stefan
    Ferrajoli, Alessandra
    Cortes, Jorge E.
    BLOOD, 2010, 116 (21) : 529 - 530
12345